SREBP2gc transcription factors and uses thereof
View Patent ↗The present invention relates to methods and compositions for modulating fertility. In particular the present invention provides cell lines and transgenic animals for use in identifying modulators of SREBP2gc transcription factors. The present invention further provides therapeutic agents that modulate SREBP2gc signaling for use as fertility modulators.
1. A method of screening one or more test compounds that alter the interaction of SREBP2gc with a proacrosin promoter, comprising:
a) providing
i) a nucleic acid sequence comprising a proacrosin promoter operably linked to a reporter gene;
ii) a SREBP2gc polypeptide; and
iii) one or more test compounds;
b) contacting said proacrosin promoter and said SREBP2gc polypeptide with said one or more test compounds in vitro; and
c) measuring expression of said reporter gene in the presence of said one or more test compounds and in the absence of said one or more test compounds, wherein a difference in expression indicates that said one or more test compounds alters the interaction of said SREBP2gc polypeptide with said proacrosin promoter.
2. The method of claim 1 , wherein said one or more test compounds decrease reporter gene expression.
3. The method of claim 1 , wherein said SREBP2gc polypeptide is produced by expression of a nucleic acid encoding said SREBP2gc polypeptide.
4. The method of claim 1 , wherein said proacrosin promoter comprises the nucleic acid sequence of SEQ ID NO: 15.
5. The method of claim 1 , wherein said proacrosin promoter comprises one or more sterol response elements.
6. The method of claim 5 , wherein said sterol response elements are mutant sterol response elements.
7. The method of claim 6 , wherein said mutant sterol response elements are non-functional.
8. A method of screening one or more test compounds that alter the interaction of SREBP2gc with a proacrosin promoter, comprising:
a) providing a cell that comprises
i) a nucleic acid sequence comprising a proacrosin promoter operably linked to a reporter gene; and
ii) a nucleic acid sequence encoding a SREBP2gc polypeptide;
b) providing one or more test compounds;
c) contacting said cell with said one or more test compounds in vitro; and
d) measuring expression of said reporter gene in the presence of said one or more test compounds and in the absence of said one or more test compounds, wherein a difference in expression indicates that said one or more test compounds alters the interaction of said SREBP2gc polypeptide with said proacrosin promoter.
9. The method of claim 8 , wherein said cell is a spermatocyte.
10. The method of claim 9 , wherein said spermatocyte is from a GC-4spc cell line.
11. The method of claim 8 , wherein said one or more test compounds decrease.
12. The method of claim 8 , wherein said proacrosin promoter comprises the nucleic acid sequence of SEQ ID NO: 15.
13. The method of claim 8 , wherein said proacrosin promoter comprises one or more sterol response elements.
14. The method of claim 13 , wherein said sterol response elements are mutant sterol response elements.
15. The method of claim 14 , wherein said mutant sterol response elements are non-functional.
16. The method of claim 1 , wherein said SREBP2gc polypeptide competes with said one or more test compounds for specific binding to said proacrosin promoter.
17. The method of claim 8 , wherein said SREBP2gc polypeptide competes with said one or more test compounds for specific binding to said proacrosin promoter.
18. A method of screening one or more test compounds that alter the interaction of SREBP2gc with a proacrosin promoter, comprising:
a) providing
i) a nucleic acid sequence comprising a proacrosin promoter operably linked to a reporter gene;
ii) a SREBP2gc polypeptide; and
iii) one or more test compounds;
b) contacting said proacrosin promoter or said SREBP2gc polypeptide with said one or more test compounds in vitro; and
c) measuring expression of said reporter gene in the presence of said one or more test compounds and in the absence of said one or more test compounds, wherein a difference in expression indicates that said one or more test compounds alters the interaction of said SREBP2gc polypeptide with said proacrosin promoter.